This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Skyworks (SWKS) in Q1 Earnings?
by Zacks Equity Research
Skyworks (SWKS) is benefiting from its portfolio strength, particularly in the 5G applications and IoT market.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Why Merck (MRK) Could Beat Earnings Estimates Again
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio (INO) focuses on developing its most advanced candidate, VGX-3100 vaccine, which has been advancing well. Reliance on partners for funds to develop its pipeline candidates is a concern.
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
Merck (MRK) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive fourth-quarter sales. However, genericization of key drugs and increasing competition are concerns.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $72.95, marking a -0.3% move from the previous day.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV
by Zacks Equity Research
J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III
by Zacks Equity Research
Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.
Dow 30 Stock Roundup: UTX, TRV, PG, JNJ Earnings Impress, IBM Revenues Decline Y/Y
by Swarup Gupta
The index traversed an eventful, yet holiday-shortened week.
Bristol-Myers (BMY) Beats Q4 Earnings, Withdraws Opdivo sBLA
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the fourth quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.
Healthcare ETFs in Focus Ahead of Q4 Earnings
by Sweta Killa
With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.
Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids
by Zacks Equity Research
Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.
J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.
Alnylam & Medison Partner to Market RNAi Products in Israel
by Zacks Equity Research
Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.
The Zacks Analyst Blog Highlights: Bank of America, Merck, Netflix, IBM and The Bank of New York Mellon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Merck, Netflix, IBM and The Bank of New York Mellon
Merck's Partner Gets FDA Nod for Herceptin Biosimilar
by Zacks Equity Research
Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.
Top Analyst Reports for Bank of America, Merck & Netflix
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Merck (MRK) and Netflix (NFLX).
Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
by Zacks Equity Research
Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.
Dow 30 Stock Roundup: JPM & AXP Earnings Disappoint, GS & UNH Impress
by Swarup Gupta
The index enjoyed another strong week of gains, increasing over three straight sessions.
Pacira's Study on Exparel Label Expansion Meets Endpoints
by Madhu Goel
Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.
Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA
by Zacks Equity Research
Roche's (RHHBY) sBLA for the label expansion of Tecentriq in combination with Abraxane for the initial treatment of NSCLC has been accepted by the FDA.
Stock Market News For Jan 15, 2019
by Zacks Equity Research
Benchmarks ended in the red on Monday as corporate earnings kicked off.
5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019
by Zacks Equity Research
Exelixis (EXEL) lead drug, Cabometyx continues to perform well.
What's in Store for Merck in 2019 After a Solid Run in '18?
by Zacks Equity Research
Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.